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IMPORTANCE Trastuzumab plus chemotherapy is the standard adjuvant treatment for
patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
While the standard duration of trastuzumab treatment is 12 months, the benefits and harms
of trastuzumab continued beyond the chemotherapy are unclear.
OBJECTIVE To evaluate the efficacy and safety of adjuvant trastuzumab continued beyond
chemotherapy in women treated with up-front chemotherapy containing a taxane and
trastuzumab.
DESIGN, SETTING, AND PARTICIPANTS Open-label, randomized (1:1) clinical trial including
women with HER2-positive breast cancer. Chemotherapy was identical in the 2 groups,
consisting of 3 cycles of 3-weekly docetaxel (either 80 or 100 mg/m2) plus trastuzumab for 9
weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide. Thereafter, no
trastuzumab was administered in the 9-week group, whereas controls received trastuzumab
to complete 1 year of administration. Disease-free survival (DFS) was compared between the
groups using a Cox model and the noninferiority approach. The estimated sample size was
2168 patients (1-sided testing, with a relative noninferiority margin of 1.3). From January 3,
2008, to December 16, 2014, 2176 patients were accrued from 7 countries.
INTERVENTION Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil,
epirubicin, and cyclophosphamide in both groups. Controls continued trastuzumab to 1 year.
MAIN OUTCOMES AND MEASURES The primary objective was DFS; secondary objectives
included distant disease–free survival, overall survival, cardiac DFS, and safety.
RESULTS In the 2174 women analyzed, median age was 56 (interquartile range [IQR], 48-64)
years. The median follow-up was 5.2 (IQR, 3.8-6.7) years. Noninferiority of the 9-week
treatment could not be demonstrated for DFS (hazard ratio, 1.39; 2-sided 90% CI, 1.12-1.72).
Distant disease–free survival and overall survival did not differ substantially between the
groups. Thirty-six (3%) and 21 (2%) patients in the 1-year and the 9-week groups,
respectively, had cardiac failure; the left ventricle ejection fraction was better maintained in
the 9-week group. An interaction was detected between the docetaxel dose and DFS;
patients in the 9-week group treated with 80 mg/m2 had inferior and those treated with 100
mg/m2 had similar DFS as patients in the 1-year group.
CONCLUSIONS AND RELEVANCE Nine weeks of trastuzumab was not noninferior to 1 year of
trastuzumab when given with similar chemotherapy. Cardiac safety was better in the 9-week
group. The docetaxel dosing with trastuzumab requires further study.
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P atients with breast cancer treated with adjuvanttrastuzumab, an antibody targeting human epidermalgrowth factor receptor 2 (HER2), and chemotherapy af-
ter surgery for localized cancer have fewer recurrences and live
longer compared with patients treated with chemotherapy
alone.1,2 The most notable adverse effect of trastuzumab
therapy is congestive heart failure (CHF), which occurs in 1%
to 3% of the patients treated in clinical trials,1,3 but the pro-
portion is higher in elderly populations with risk factors for
CHF.4 Trastuzumab-related decrease in the cardiac left ven-
tricular ejection fraction (LVEF) usually resolves after drug
discontinuation and initiation of therapy for CHF.5-7
Adjuvant trastuzumab is recommended to be adminis-
tered for 1 year and in part concomitantly with chemotherapy.8,9
The choice of this duration was arbitrary10 in the trials
that established the current standard 12-month duration.11-13
While the optimal duration remains unknown, 6 months of
adjuvant trastuzumab did not lead to noninferior survival out-
comes compared with 1-year administration in randomized
trials, although the results tended to favor the longer
duration,14,15 and 2-year administration was not superior to 1 year
of administration.16
Observations from in vitro studies,17,18 randomized trials
in the treatment of advanced breast cancer,19,20 and data from
1 adjuvant trial21 suggest that concomitant administration of
a taxane with trastuzumab improves efficacy, and may be syn-
ergistic. In 2 randomized trials22,23 the experimental group pa-
tients were treated with trastuzumab and a concomitant taxane
and received no trastuzumab after chemotherapy, whereas the
standard group patients were treated with trastuzumab both
during chemotherapy and after chemotherapy for a total du-
ration of 1 year. Neither trial found the standard group to have
superior disease-free survival (DFS) or overall survival (OS),
but these trials had relatively limited power. We studied in the
present Synergism or Long Duration (SOLD) trial the benefits
and harms of adjuvant single-agent trastuzumab continued
beyond chemotherapy in a patient population treated with up-
front chemotherapy containing docetaxel and trastuzumab.
The study hypothesis was that a brief course of trastuzumab,
administered concomitantly with potentially synergistic
chemotherapy, leads to similar efficacy as chemotherapy plus




Patients who had histologically confirmed HER2-positive breast
cancer with either regional node-positive or node-negative dis-
ease and with cancer size 5 mm or greater were eligible (when
size was 6-10 mm, histological grade was required to be 2 or
3). Cancer HER2 positivity was verified by demonstrating either
the presence of ERBB2/HER2 amplification using in situ hy-
bridization or strong HER2 protein expression by immunohis-
tochemical analysis (a score of 3+ on a scale from negative to
3+) according to the institutional guidelines. Other eligibility
criteria included age 18 years or older; World Health Organi-
zation performance score 0 or 1 (on a scale of 0-5); and ad-
equate renal, hepatic, and bone marrow function. An LVEF of
at least 50% was required (or within the institutional refer-
ence range). Patients with clinically significant cardiac dis-
ease were excluded. Other exclusion criteria included pres-
ence of distant metastases, neoadjuvant systemic therapy, and
history of another malignant neoplasm within the past 5 years.
Independent ethics committees of the participating hospitals
and the relevant medical authorities of the participating coun-
tries approved the study. All patients provided written in-
formed consent prior to study inclusion.
Study Procedures
The primary objective in this open-label phase 3 trial was DFS,
defined as the interval between the date of randomization and
date of diagnosis of invasive cancer recurrence (distant recur-
rence, locoregional recurrence, contralateral breast cancer, or
any invasive second cancer) or death if the patient died prior
to recurrence. The secondary objectives included distant dis-
ease–free survival (DDFS, the time from randomization to the
date of first diagnosis of distant recurrence of breast cancer, or
to death), cardiac DFS (the period from randomization to the
date of a cardiac event, cancer recurrence, or death; a cardiac
event was defined as CHF necessitating medication or medical
intervention, myocardial infarction, cardiac or coronary ar-
tery surgery, or stenting), OS (the period from randomization
to the date of death), and treatment safety.
Patients were randomized centrally with blinded com-
puter-assisted allocation to the study groups. Randomiza-
tion (1:1) was performed using dynamic minimization, with a
90% chance of allocation to the group with the lowest count.
Patients were stratified at randomization between the
groups by axillary nodal status, HER2 analysis method (in
situ hybridization or immunohistochemical analysis), can-
cer estrogen receptor expression (positive vs negative), and
study center.
Chemotherapy was identical in the groups. It consisted of
3 cycles of 3-weekly docetaxel given concomitantly with
trastuzumab, followed by 3 cycles of 3-weekly fluorouracil, epi-
rubicin hydrochloride, and cyclophosphamide (FEC). The only
Key Points
Question Does administration of trastuzumab concomitantly with
a taxane for a brief period (9 weeks) lead to similar survival
outcomes as chemotherapy and 1 year of trastuzumab in women
with early human epidermal growth factor receptor 2–positive
breast cancer?
Findings In this randomized clinical trial including 2174 women,
both treatments were associated with high 5-year distant
disease–free survival and overall survival rates, but the 9-week
trastuzumab regimen resulted in a shorter disease-free survival
than the 1-year regimen. The shorter treatment was associated
with fewer cardiac adverse effects and better maintained cardiac
function.
Meaning Trastuzumab continued beyond chemotherapy
increases efficacy but may lead to more cardiac adverse effects.
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difference in the treatment between the groups was that in the
experimental group (the 9-week group) no further trastuzumab
was given after completion of chemotherapy, whereas in the
standard treatment group (1-year group) trastuzumab was given
to complete 1 year of administration (for a total of 51 weeks).
The docetaxel dose was prespecified for each center, either
80 or 100 mg/m2 intravenously, based on center preference.
Use of the starting dose of 100 mg/m2 in patients younger than
60 years and 80 mg/m2 among those 60 years or older was al-
lowed, provided that this practice was followed throughout the
study. FEC consisted of intravenous fluorouracil (600 mg/
m2), epirubicin hydrochloride (75 mg/m2), and cyclophospha-
mide (600 mg/m2), each given on day 1 of the 3-week cycle.
Intravenous trastuzumab was administered with docetaxel
either weekly or 3-weekly, or subcutaneously 3-weekly (weekly:
first dose 4 mg/kg, subsequently 2 mg/kg; 3-weekly: first dose
8 mg/kg, subsequently 6 mg/kg; 3-weekly subcutaneously:
each dose 600 mg regardless of body weight). When
trastuzumab was administered after chemotherapy (stan-
dard group only), it was given 3-weekly 14 times (either intra-
venously or subcutaneously; intravenously: first dose 8 mg/
kg, subsequently 6 mg/kg; subcutaneously: 600 mg regardless
of body weight).
Hematopoietic growth factor support was permitted at the
discretion of the investigator. Patients with estrogen receptor–
positive and/or progesterone receptor–positive cancer re-
ceived adjuvant endocrine therapy for a minimum of 5 years
on completion of chemotherapy. The choice of endocrine
therapy was at the treating physician’s discretion. The insti-
tutional criteria for hormone receptor–positive cancer were fol-
lowed when the decision about adjuvant endocrine treat-
ment was made, but tumors with at least 10% positive cancer
cells by immunohistochemical analysis were considered re-
ceptor positive for the stratification. Locoregional radio-
therapy was given according to institutional practice. In the
1-year group, single-agent trastuzumab was started 3 weeks (±1
week) after the last FEC cycle.
Adverse effects were graded according to the Common Ter-
minology Criteria for Adverse Events, version 3.0. Docetaxel
and FEC doses were reduced 20% in case of febrile neutrope-
nia, neutropenic infection, grade 4 neutropenia lasting lon-
ger than 7 days, any grade 3 or 4 nonhematological toxic ef-
fect, or any treatment-related toxic effect that resulted in
hospitalization. Trastuzumab doses were not reduced de-
spite docetaxel dose reduction. When docetaxel administra-
tion was deferred, trastuzumab administration was also de-
ferred. In the 1-year group no trastuzumab dose reductions
were performed, but trastuzumab was discontinued when
grade 3 or 4 nonhematological toxic effects considered
trastuzumab related occurred, or when a grade 3 or 4 cardiac
event, symptomatic cardiac failure, or cardiac failure neces-
sitating medical management took place, or when the LVEF
decreased more than 10 percentage points from the baseline
value to a value less than 50%, or to less than 45% from any
baseline value.
Staging examinations were done according to the institu-
tional practice. However, computed tomography or radiogra-
phy of the chest; isotope bone scan or skeletal radiography;
and computed tomography, magnetic resonance imaging, or
ultrasound of the liver were mandatory at screening for pa-
tients with at least 4 positive axillary nodes, metastases in the
internal mammary, infraclavicular, or supraclavicular nodes,
or when the primary tumor was larger than 5 cm, or classified
as pT4. The LVEF was measured at baseline, at study weeks
18, 31, 43, and 61, and 36 months after study entry with either
echocardiography (1295 patients [60%]) or isotope cardiogra-
phy (876 patients [40%]), using the same method through-
out the study. The patients were scheduled for a minimum of
8 years of follow-up after randomization.
Statistical Analysis
The study was designed as a superiority trial with an esti-
mated recruitment period of 4 years. The sample calculation
was carried out considering a 4% difference in DFS between
the groups, 80% vs 84% after 5 years of follow-up, a power of
0.80, a 2-sided significance level of .05, a hazard ratio (HR) of
0.781, and 3% of the patients estimated to be lost to follow-up
or to discontinue the study. With these assumptions, 516 events
and a sample size of 3000 patients (1500 per group) were
estimated to be needed.
These power calculations were revised and the study pro-
tocol (Supplement 1) was amended on February 21, 2014, be-
cause new data2,24 suggested that the assumptions made for
DFS were too low, and it seemed unreasonable to assume that
DFS in the experimental group could be superior to the stan-
dard arm because trastuzumab-related cardiac toxic effects
were reported relatively rarely. Therefore, a noninferiority de-
sign seemed a more reasonable approach. Coincidentally, pa-
tient accrual was slower than anticipated, and the longer-than-
expected accrual period affected the power calculations. A
5-year DFS of 85.0% was estimated in the 1-year group,2 and
absolute 5-year DFS differences of less than 4% were not con-
sidered clinically significant, leading to a relative noninferi-
ority margin of 1.3. The noninferiority margin corresponding
to the true (observed) 5-year DFS rate of 88.7% is 1.385 (Sta-
tistical Analysis Plan in Supplement 1). Based on an esti-
mated accrual duration of 7.5 years, 1-sided testing,25,26 a rela-
tive noninferiority margin of 1.3, and a 3% dropout rate, the
final sample size was 2168 patients (1084 patients per group).
The primary analysis was planned for when approximately 366
DFS events were reached or when the last patient entered
was followed up for 2.0 years after randomization, which-
ever occurred first. The sample size was calculated using
nQuery Advisor, version 6.0 (Statistical Solutions Ltd).
Efficacy analyses were based on the intention-to-treat prin-
ciple. Exploratory subgroup analyses were defined in the Sta-
tistical Analysis Plan approved prior to the study analysis on
February 28, 2017, but not in the original study protocol. The
safety population included patients who received at least 1 dose
of the study drugs. Frequency tables were analyzed using the
χ2 test. The LVEF between the groups with time was com-
pared with repeated-measures analysis of variance. Survival
between groups was compared using the Kaplan-Meier life-
table method and with a Cox proportional hazards model ad-
justed with the stratification factors. The subgroup analyses
were done by including the treatment group, the subgroup
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variable, and their interaction in the Cox model. Survival analy-
sis results are provided with a 90% 2-sided confidence inter-
val (corresponding to the 1-sided 95% upper limit used in the
evaluation of noninferiority). The P values are 2 sided and not
adjusted for multiple testing. Statistical analyses were per-
formed with SAS, version 9.3 for Windows (SAS Institute, Inc).
Results
Between January 3, 2008, and December 16, 2014, 2176 pa-
tients were accrued from 65 centers (9-week group, 1087; 1-year
group, 1089). On December 16, 2016, when the last patient ac-
crued had been followed up for 2 years after randomization,
fewer than the anticipated number of DFS events were
reported, and therefore the study was analyzed as per the pro-
tocol based on the landmark follow-up time. December 31,
2016, was set as the data collection cutoff date.
Two patients with overt metastases at the time of study
entry were excluded from the intention-to-treat analysis
(Figure 1). Two patients in the 9-week group and 1 in the 1-year
group were lost to follow-up. The patient and breast cancer
characteristics were similar in the groups; most had axillary
node–negative cancer (Table 1). Adjuvant endocrine therapy
was administered to 714 (66%) and 727 (67%) participants af-
ter chemotherapy in the 9-week and 1-year groups, respec-
tively, and locoregional radiotherapy to 824 (76%) and 811
(74%).
Survival
During a median follow-up time of 5.2 years (interquartile range
[IQR], 3.8-6.7 years), 140 and 105 DFS events were recorded









Age, median (IQR), y 56 (49-64) 56 (48-63)
Weight, median (IQR), kg 70 (62-80) 70 (61-79)
Race
White 1061 (98) 1066 (98)
Other 24 (2) 23 (2)
Menopausal status
Premenopausal 353 (33) 364 (33)
Postmenopausal 731 (67) 724 (66)
Not available 1 (<1) 1 (<1)
World Health Organization
performance status
0 975 (90) 963 (88)
1 102 (9) 112 (10)
Not available 8 (1) 14 (1)
Breast tumor diameter, mm
≤10 129 (12) 155 (14)
11-20 473 (44) 453 (42)
21-50 447 (41) 452 (42)
>50 36 (3) 29 (3)
No. of axillary lymph nodes with
cancer
0 647 (60) 649 (60)
1-3 322 (30) 320 (29)
>3 116 (11) 120 (11)
Stage
I 427 (39) 430 (39)
II 529 (49) 528 (48)
III 129 (12) 131 (12)
Histological grade
1 26 (2) 27 (2)
2 340 (31) 327 (30)
3 714 (66) 731 (67)
Not available 5 (<1) 4 (<1)
Histological type
Ductal 1000 (92) 1000 (92)
Lobular 44 (4) 49 (4)
Other 39 (4) 39 (4)
Not available 2 (<1) 1 (<1)
Estrogen receptor status
Positive 711 (66) 723 (66)
Negative 374 (34) 366 (34)
Progesterone receptor status
Positive 504 (46) 517 (47)
Negative 576 (53) 565 (52)
Not available 5 (<1) 7 (1)
HER2 status
Positive 1078 (99) 1084 (100)
Negative 0 1 (<1)
Unconfirmed, IHC++ 7 (1) 4 (1)
Abbreviations: HER2, human epidermal growth factor-2; IHC,
immunohistochemistry; IQR, interquartile range.
a Percentages may not total 100 because of rounding.
Figure 1. CONSORT Diagram
1085 Included in the intention-to-
treat population









942 Were alive without cancer
recurrence
140 Had cancer recurrence or died
58 Died
34 Died of breast cancer
983 Were alive without cancer
recurrence
105 Had cancer recurrence or died
44 Died
33 Died of breast cancer
1087 Randomized to receive 9 wk
of trastuzumab
1089 Randomized to receive 51 wk
of trastuzumab
2 Excluded
2 Had distant metastases
2 Lost to follow-up
1 Lost to follow-up
2176 Randomized
The numbers of individuals screened for eligibility and the reasons for exclusion
were not captured.
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in the 9-week and 1-year groups, respectively (Table 2). Non-
inferiority of the 9-week treatment as compared with the 1-year
treatment was not demonstrated (5-year DFS, 88.0% vs 90.5%,
respectively; HR, 1.39; 2-sided 90% CI, 1.12-1.72) (Figure 2).
When the analysis was adjusted for axillary nodal status and
cancer estrogen receptor content using a Cox model, the HR
was 1.42 (90% CI, 1.15-1.76). The DDFS and OS did not differ
substantially between groups (5-year DDFS, 93.2% vs 94.2%;
HR, 1.24; 90% CI, 0.93-1.65; 5-year OS, 94.7% vs 95.9%; HR,
1.36; 90% CI, 0.98-1.89). Five-year cardiac DFS was 86.6% and
87.5%, respectively (HR, 1.16; 90% CI, 0.96-1.40) (eFigure 1 in
Supplement 2).
The subgroup analyses on DFS generally favored the 1-year
treatment duration (Figure 3). The subgroups were formed
with a stratification factor (cancer estrogen receptor content)
or factors predefined in the study Statistical Analysis Plan
(docetaxel dosing, the number of axillary nodes with cancer,
center accrual, patient age at study entry, and cancer stage)
(Supplement 1). A significant interaction (P = .007) was found
between docetaxel dosing and DFS; the 1678 patients who re-
ceived docetaxel, 80 mg/m2, had inferior and the 480 who re-
ceived 100 mg/m2 had similar DFS to patients in the 1-year
group treated with the same docetaxel dosing (eFigure 2 in
Supplement 2).
Treatment Tolerance
Twenty-two (2%) of the 1085 patients in the 9-week group and
42 (4%) of the 1089 patients in the 1-year group had a protocol-
defined cardiac adverse event (P = .01). Most were CHF (21 and
36, respectively). The LVEF was better maintained in the
9-week group, with less decrease in LVEF during follow-up
Table 2. Cancer Recurrence and Survival
Variable
No. (%)







Any recurrence or deathb 140 (13) 105 (10) 1.39 (1.12-1.72)
Distant recurrence 73 (7) 61 (6) 1.24 (0.93-1.65)
Locoregional recurrence 17 (2) 13 (1) 1.35 (0.74-2.48)
Contralateral breast cancer 15 (1) 7 (1) 2.24 (1.05-4.75)
Second cancer 27 (3) 24 (2) 1.16 (0.73-1.84)
Death without cancer 14 (1)c 5 (0) 2.88 (1.22-6.78)
Death from any cause 58 (5) 44 (4) 1.36 (0.98-1.89)
Death from breast cancer 34 (3) 33 (3) 1.06 (0.71-1.59)
Death from other caused 24 (2) 11 (1) 2.24 (1.23-4.08)
a Calculated with an unadjusted Cox
proportional hazards model.
b Six patients in the 9-week group
and 5 patients in the 1-y group had 2
disease-free survival events.
c The cause of death was unknown in
3 cases.
d Eleven patients died of second
cancer, 5 of infection, 2 of a cardiac
cause, 3 of other causes, and 3 of an
unknown cause in the 9-week
group; in the 1-year group, 6 died of
second cancer, 2 of infection, 1 of a
cardiac cause, and 2 of other causes.





































































































































Trastuzumab for 51 wk
Trastuzumab for 51 wk Trastuzumab for 51 wk
Trastuzumab for 9 wk
Trastuzumab for 9 wk Trastuzumab for 9 wk
HR, 1.39 (90% CI, 1.12-1.72) HR, 1.24 (90% CI, 0.93-1.65) HR, 1.36 (90% CI, 0.98-1.89)
Figure 3. Disease-Free Survival in Prespecified Subgroups
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(mean LVEF was 63% in the 9-week group and 61% in the
1-year group 61 weeks after study entry; P < .001) (eFigure 3
in Supplement 2). As expected, chemotherapy-related
adverse effects were similar in both groups (eTables 1 and 2
in Supplement 2). A total of 185 (17%) and 203 (19%)
patients in the 9-week and 1-year groups had the docetaxel
dose reduced on 1 or more occasion, respectively, and 128
(12%) and 120 (11%) had FEC administered at a reduced
dose.
Ninety-six (9%) patients in the 9-week group and 217 (20%)
in the 1-year group discontinued scheduled trastuzumab ad-
ministration, usually due to adverse effects. Most patients com-
pleted all 6 chemotherapy cycles (9-week group, 1041; 1-year
group, 1038).
Discussion
Women with HER2-positive breast cancer treated with adju-
vant chemotherapy and trastuzumab for 1 year had higher
DFS compared with patients who received trastuzumab dur-
ing chemotherapy only. Because the only difference
between the regimens was administration of trastuzumab
after chemotherapy in the 1-year group, postchemotherapy
trastuzumab improved DFS despite prior trastuzumab
plus docetaxel. The HR for OS was in agreement with
that for DFS, although this analysis was based on a relatively
small number of events. The numbers of deaths considered
to have resulted from breast cancer were similar in
the groups. The 9-week regimen was associated with
fewer cardiac adverse effects and a smaller decline in the
LVEF.
The numerical difference in the DFS events recorded be-
tween the groups was 35 (140 [13%] vs 105 [10%]). The num-
ber of distant recurrences was numerically higher in the 9-week
group (73 [7%] vs 61 [6%] events). The numbers of death from
a cause other than breast cancer (24 [2%] vs 11 [1%]) and the
numbers of contralateral breast cancers (15 [1%] vs 7 [1%]) were
also higher in the 9-week group, which may have been due to
chance because there are no biological explanations for a higher
incidence of these events with less trastuzumab. There was
only approximately 1% absolute difference between the groups
in the 5-year DDFS and OS rates, which are clinically relevant
survival end points. Considering this, patients who are un-
able to complete the longer duration of trastuzumab therapy
due to treatment toxic effects or other reasons usually still have
a favorable outcome.
We found an interaction between docetaxel dosing and
DFS. A subgroup of the patients were treated in centers
where the 100 mg/m2 docetaxel dose was preferred, and in
this patient population the 1-year duration of trastuzumab
did not yield better DFS than the 9-week duration. This
observation needs to be viewed with caution because this is
a subgroup analysis and site-related confounding factors
cannot be excluded. Other trials have suggested that
docetaxel and trastuzumab have additive or synergistic
effects for breast cancer.17-21 In the Short-HER trial, which
compared a regimen of trastuzumab given for 9 weeks con-
comitantly with 100 mg/m2 of docetaxel27 vs a modified
standard chemotherapy regimen including 1 year of
trastuzumab administration,2 patients assigned to 9 weeks
of trastuzumab did not have inferior DFS or OS compared
with those treated with the 1-year trastuzumab regimen
despite larger cumulative doses of epirubicin and docetaxel
administered in the 1-year trastuzumab group.23 Similarly,
in the small randomized E2198 trial, in which the patients
first received 12 weeks of a full dose of 3-weekly paclitaxel
(175 mg/m2) and concomitant trastuzumab, followed by 4
cycles of doxorubicin and cyclophosphamide, or the afore-
mentioned treatment followed by 1 year of trastuzumab,
trastuzumab continued beyond chemotherapy did not
improve DFS or OS.22
Collectively, these results from SOLD, E2198, and Short-
HER suggest that a relatively high dose of the coadminis-
tered taxane should be given with trastuzumab when a brief
course of trastuzumab will be evaluated in further clinical
trials. The biological explanation for the interaction
between taxane dosing and trastuzumab remains specula-
tive. Trastuzumab action likely involves the host immune
system and activation of antibody-dependent cellular
cytotoxicity.28,29 Hypothetically, a large enough dose of a
taxane might reduce the numbers of immunosuppressive
lymphocytes and other cells in the cancer microenviron-
ment to a level that allows immune system activation for a
period long enough to enhance trastuzumab efficacy.
Limitations
The study has some limitations. Many patients had node-
negative cancer. Some investigators may have preferred not
to enroll patients with a high risk of cancer recurrence, and
some study centers participated in a concurrent trial.30 The
likely too low estimation for DFS and the longer-than-
planned accrual time led to a revision of the study design
and the power calculations during the study. The protocol-
defined median follow-up time, rather than the number of
events, triggered the analysis because it seemed not pos-
sible to reach the planned number of events within a
reasonable time frame, leading to a lower-than-planned
study power. Yet, the present analysis seems to be
adequately powered for the primary objective of evaluating
noninferiority.
Conclusions
Noninferiority of 9-week administration of adjuvant
trastuzumab, when given with docetaxel, could not be dem-
onstrated compared with chemotherapy and 1-year duration
of trastuzumab therapy. Although the shorter regimen was as-
sociated with fewer cardiac toxic effects and there was little
absolute difference in clinically important survival out-
comes, DDFS and OS, in the overall assessment chemo-
therapy plus 1 year of anti-HER2 therapy should remain the
standard treatment. Adequate dosing of the partner chemo-
therapy agents is likely important and requires further
evaluation.
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